Now, A more accurate, quantificable and objective method for determining the PD-L1 positive rate is in urgent need in clinic, where those such as examination of PD-L1 positive circulating tumor cells with flow cytometry and mismatch-repair deficiency(MMR) hold promise [39, 40]. Here, MRC1 is linked to neoplasm.